Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Zafgen Inc    ZFGN

 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
03/20/2017 03/21/2017 03/22/2017 03/23/2017 03/24/2017 Date
4.58(c) 4.57(c) 4.7(c) 4.72(c) 4.6(c) Last
203 862 344 709 326 963 169 016 198 792 Volume
+5.53% -0.22% +2.84% +0.43% -2.54% Change
More quotes
Financials ($)
Sales 2017 -
EBIT 2017 -57,3 M
Net income 2017 -60,3 M
Finance 2017 69,2 M
Yield 2017 -
Sales 2018 -
EBIT 2018 -63,8 M
Net income 2018 -63,5 M
Finance 2018 111 M
Yield 2018 -
P/E ratio 2017 -
P/E ratio 2018
EV / Sales2017 0
EV / Sales2018 0
Capitalization 126 M
More Financials
Company
Zafgen, Inc. is a biopharmaceutical company, which engages in the development of anti-obesity therapeutics that restores normal fat metabolism and regulatory pathways.Its product: Beloranib, which is under phase 2 clinical development as a treatment for obesity and hyperphagia in Prader-Willi... 
More about the company
Surperformance© ratings of Zafgen Inc
Trading Rating : Investor Rating : -
More Ratings
Latest news on ZAFGEN INC
03/10 ZAFGEN : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS..
03/10 ZAFGEN : reports 4Q loss
03/09 ZAFGEN, INC. : Results of Operations and Financial Condition, Financial Statemen..
03/09 Zafgen Reports Fourth Quarter and Full Year 2016 Financial Results
03/02 Zafgen to Host Conference Call to Discuss Fourth Quarter and Full Year 2016 F..
02/28 Zafgen to Present at Upcoming Investor Conferences
02/11 ZAFGEN : U.S. Patents Awarded to Inventors in New Jersey (Feb. 11)
02/09 Zafgen to Present at the Leerink Partners 6th Annual Global Healthcare Confer..
2016 ZAFGEN : reports 3Q loss
2016 ZAFGEN : Management's Discussion and Analysis of Financial Condition and Results..
More news
Sector news : Bio Therapeutic Drugs
03/18DJAMGEN : Repatha Study Shows Reduced Risk of Heart Attack, Stroke -- 3rd Update
03/17DJAMGEN : Repatha Study Shows Reduced Risk of Heart Attack, Stroke -- 2nd Update
03/17DJAMGEN : Money-Back Guarantee
03/17DJAmgen's Repatha Study Shows Reduced Risk of Heart Attack, Stroke -- Update
03/17DJAmgen's Repatha Study Shows Reduced Risk of Heart Attack, Stroke
More sector news : Bio Therapeutic Drugs
Latest Tweets
03/10% movers UP $BPT $KMI/W $WG $SALT $GCO $SGY $PIR $WLDN $SHLD $CTRN $ZFGN $TTP..
1
03/10Healthcare - Top Gainers / Losers as of 12:00 pm
1
03/10$ZFGN: Zafgen beats by $0.12, reports no revenue  
03/09#EquityResearch Zafgen, Inc. 2016 Q4 - Results - Earnings Call Slides $ZFGN  
03/09Zafgen, Inc. 2016 Q4 - Results - Earnings Call Slides  
More tweets
Qtime:27
News from SeekingAlpha
03/14 Near-Term Opportunity In Zafgen
03/10 Midday Gainers / Losers
03/10 HEALTHCARE - TOP GAINERS / LOSERS AS : 00 pm
03/09 Zafgen's (ZFGN) CEO Thomas Hughes on Q4 2016 Results - Earnings Call Transcri..
03/09 Zafgen, Inc. 2016 Q4 - Results - Earnings Call Slides
Advertisement
Chart ZAFGEN INC
Duration : Period :
Zafgen Inc Technical Analysis Chart | ZFGN | US98885E1038 | 4-Traders
Full-screen chart
Technical analysis trends ZAFGEN INC
Short TermMid-TermLong Term
TrendsBullishBullishBearish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 5
Average target price 4,80 $
Spread / Average Target 4,3%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Thomas E. Hughes President, Chief Executive Officer & Director
Peter Barrett Chairman
Patricia L. Allen CFO, Treasurer & Principal Accounting Officer
Dennis D. Kim Chief Medical Officer
Bruce Lee Booth Independent Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
ZAFGEN INC44.65%126
AMGEN, INC.13.36%122 060
CELGENE CORPORATION6.59%95 986
GILEAD SCIENCES, INC.-5.73%88 240
REGENERON PHARMACEUTIC..1.61%39 568
ACTELION LTD24.44%29 804
More Results